Sex Differences in Cardiovascular Outcomes and Cholesterol-Lowering Efficacy of PCSK9 Inhibitors
JACC: Advances · 2023-11 · 2 (9) · 100669
DOI: 10.1016/j.jacadv.2023.100669 ↗Kurz gefasst
Fachartikel in der Zeitschrift JACC: Advances, 2023-11. Verfasst von Frederick Berro Rivera und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Lincoln Medical Center, Bronx, New York, USA. Die Arbeit wurde bisher 35-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background
Guideline-recommended low-density lipoprotein cholesterol (LDL-C) thresholds are often not achieved in women. The proprotein convertase subtilisin/kexin type-9 inhibitor (PCSK9i) monoclonal antibodies can help further reduce LDL-C and major adverse cardiovascular events (MACE) although differences in efficacy by sex and type are less understood.
Objectives
The authors sought to determine if there are differences in the efficacy of LDL-C lowering and reduction in the risk of MACE by sex and type of PCSK9i.
Methods
A comprehensive literature search was done through October 17, 2022, for published trials comparing PCSK9i vs control. Outcomes assessed were LDL-C reduction and incidence of MACE following the use of PCSK9i vs placebo, stratified by sex and type of PCSK9i used.
Results
We identified 16 trials with 54,996 adults, and 15,143 (27.5%) of them were female. PCSK9i significantly reduced MACE compared to placebo in both women (HR: 0.86, 95% CI: 0.74-0.97, P < 0.001) and men (HR: 0.85, 95% CI: 0.79-0.91, P < 0.001) with no significant sex difference (MD -0.01, 95% CI: -0.14 to -0.13, P = 0.930). PCSK9i also significantly reduced LDL-C levels in both sexes at 12 weeks (females: MD -62.57, 95% CI: -70.24 to -54.91, P < 0.001; males: MD -66.19, 95% CI: -72.03 to -60.34, P < 0.001) and 24 weeks (females: MD -47.52, 95% CI: -52.94 to -42.09, P < 0.001; males: MD -54.07, 95% CI: -59.46 to -48.68, P < 0.001). Significant sex difference was seen in the LDL reduction of PCSK9i for both 12 weeks (males vs females: MD -4.55, 95% CI: -7.34 to -1.75, P < 0.01) and 24 weeks (males vs females: MD -7.11, 95% CI: -9.99 to -4.23, P < 0.001).
Conclusions
The use of PCSK9i results in significant LDL-C and MACE reduction in both males and females. While there is no significant sex difference in MACE reduction, LDL-C reduction is greater in males than in females. Our data support the equal use of PCSK9i in all eligible patients, regardless of sex.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Medicine, Lincoln Medical Center, Bronx, New York, USA.
- Department of Medicine, Cebu Institute of Medicine, Cebu City, Cebu, Philippines.
- Department of Internal Medicine, Texas Tech University Health Sciences Center El Paso, El Paso, Texas, USA.
- Department of Medicine, University of the Philippines System, Manila, National Capital Region, Philippines.
- Section of Endocrinology, Diabetes & Metabolism, UC Davis Health Systems, Davis, California, USA.
- Department of Cardiology, Houston Methodist DeBakey Heart & Vascular Center, Houston, Texas, USA.
Zitieren
APA
Rivera, F. B., Cha, S. W., Aparece, J. P., Rocimo, A., Ong, B. A., Golbin, J. M., Alfonso, P. G., Enkhmaa, B., Khan, S. U., Cainzos-Achirica, M., Volgman, A. S., Navar, A. M., & Shah, N. P. (2023). Sex Differences in Cardiovascular Outcomes and Cholesterol-Lowering Efficacy of PCSK9 Inhibitors. JACC: Advances, 2(9), 100669. https://doi.org/10.1016/j.jacadv.2023.100669
Vancouver
Rivera FB, Cha SW, Aparece JP, Rocimo A, Ong BA, Golbin JM, et al. Sex Differences in Cardiovascular Outcomes and Cholesterol-Lowering Efficacy of PCSK9 Inhibitors. JACC: Advances. 2023;2(9):100669. doi:10.1016/j.jacadv.2023.100669
BibTeX
@article{Rivera2023,
author = {Rivera, Frederick Berro and Cha, Sung Whoy and Aparece, John Paul and Rocimo, Aubrey and Ong, Bradley Ashley and Golbin, Jem Marie and Alfonso, Pia Gabrielle and Enkhmaa, Byambaa and Khan, Safi U and Cainzos-Achirica, Miguel and Volgman, Annabelle Santos and Navar, Ann Marie and Shah, Nishant P},
title = {Sex Differences in Cardiovascular Outcomes and Cholesterol-Lowering Efficacy of PCSK9 Inhibitors},
journal = {JACC: Advances},
year = {2023},
volume = {2},
number = {9},
pages = {100669},
doi = {10.1016/j.jacadv.2023.100669}
}
EUVIMED